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Abstract: Cells grow in response to nutrients or growth factors, whose presence is detected and communicated by elabo-
rate signaling pathways. Protein kinases play crucial roles in processes such as cell cycle progression and gene expression, 
and misregulation of such pathways has been correlated with various diseased states. Signals intended to promote cell 
growth converge on ribosome biogenesis, as the ability to produce cellular proteins is intimately tied to cell growth. Part 
of the response to growth signals is therefore the coordinate expression of genes encoding ribosomal RNA (rRNA) and ri-
bosomal proteins (RP). A key player in regulating cell growth is the Target of Rapamycin (TOR) kinase, one of the gate-
keepers that prevent cell cycle progression from G1 to S under conditions of nutritional stress. TOR is structurally and 
functionally conserved in all eukaryotes. Under favorable growth conditions, TOR is active and cells maintain a robust 
rate of ribosome biogenesis, translation initiation and nutrient import. Under stress conditions, TOR signaling is sup-
pressed, leading to cell cycle arrest, while the failure of TOR to respond appropriately to environmental or nutritional sig-
nals leads to uncontrolled cell growth. Emerging evidence from Saccharomyces cerevisiae indicates that High Mobility 
Group (HMGB) proteins, non-sequence-specific chromosomal proteins, participate in mediating responses to growth sig-
nals. As HMGB proteins are distinguished by their ability to alter DNA topology, they frequently function in the assembly 
of higher-order nucleoprotein complexes. We review here recent evidence, which suggests that HMGB proteins may func-
tion to coordinate TOR-dependent regulation of rRNA and RP gene expression. 
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INTRODUCTION 
  Eukaryotic cell growth is regulated by intricate signaling 
pathways in response to nutrient levels, environmental stress 
and the presence of growth factors. Several protein kinases 
contribute to such signaling, including the target of rapamy-
cin (TOR) kinase, a highly conserved serine/threonine kinase 
that plays a central role in the control of cell growth (re-
viewed in [1-3]). TOR is structurally and functionally con-
served in all eukaryotes, and in mammalian cells, its dys-
regulation has been linked to many forms of cancer (re-
viewed in [4-7]). When growth conditions are favorable, 
TOR is active; this results in cells supporting ribosome bio-
genesis, translation initiation and nutrient import. Under 
stress conditions, TOR signaling is suppressed, resulting in 
cell cycle arrest. The failure of TOR to respond appropriately 
to environmental factors or nutritional signals leads to un-
controlled cell growth, as TOR signaling controls many as-
pects of cellular metabolism, including initiation of transla-
tion and transcription.  
  Up to 80% of the transcriptional machinery in Sac-
charomyces cerevisiae is dedicated to synthesis of ribosomal 
components - rRNA by RNA polymerase (Pol) I, ribosomal 
proteins by Pol II and 5S ribosomal RNA and tRNA by Pol 
III - while in the proliferating mammalian cell, as much as 
50% of nuclear transcription is committed to this goal. What  
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has also becomes increasingly evident is that ribosome bio-
genesis is an important determinant of cell growth; to main-
tain steady growth in response to favorable conditions, about 
2000 ribosomes need to be synthesized per minute. While 
the role of TOR in regulating the synthesis of ribosomal 
components is well established, the mechanism by which all 
three polymerases are coordinately regulated in response to 
appropriate stimuli remains to be fully elucidated. As re-
viewed here, emerging evidence points to a role for high 
mobility group (HMGB) proteins in mediating such coordi-
nated regulation in response to TOR signaling. 
TOR COMPLEXES 
  Both yeast and mammals contain two functionally and 
structurally distinct TOR complexes, TOR complex 1 
(TORC1) and TOR complex 2 (TORC2), each composed of 
TOR as well as subunits that determine downstream sub-
strates [8]. TORC1 controls cell growth via a rapamycin-
sensitive signaling pathway [9-11] while TORC2 controls 
the organization of the actin cytoskeleton through a rapamy-
cin-insensitive signaling pathway [12-15]. While higher eu-
karyotes encode a single TOR homolog, yeast encodes two 
TOR proteins, TOR1 and TOR2, either of which may be-
come components of TORC1. TOR1 and TOR2 are therefore 
functionally redundant as components of TORC1, which 
responds to rapamycin by generating cellular responses akin 
to those induced by stress or starvation, including down-
regulation of translation, inhibition of ribosome biogenesis, 
and specific changes in gene expression. In contrast, yeast Coordination of Ribosomal Protein  Current Genomics, 2009, Vol. 10, No. 3    199 
TOR2 is uniquely required for mediating the cell cycle-
dependent polarization of the actin cytoskeleton and is the 
kinase component of TORC2 [13, 16, 17].  
  The ~280 kDa TOR proteins share 40-60% sequence 
identity and contain several domains. The N-terminal do-
main contains a number of HEAT motifs (for Huntington, 
EF3, A subunit of PP2A, TOR1), required for proper subcel-
lular localization [18]. A central FAT domain (for FRAP, an 
earlier name for mammalian TOR, ATM, TRAP) may medi-
ate protein-protein interactions [18, 19]. The C-terminal do-
main harbors the serine/threonine protein kinase activity. 
TOR proteins belong to the phosphatidyl inositol kinase-
related kinase (PIKK) family, as their catalytic domain re-
sembles that of the phosphatidyl inositol 3-kinases (PI3K). 
The kinase domain is immediately preceded by the FKBP12-
rapamycin binding domain (FRB). Both TORC1 and TORC2 
are multimeric complexes (Fig. (1); [14, 20]). 
  The response to rapamycin requires that the drug first 
combine with the intracellular receptor FKBP12 [9, 21]. 
FKBP12-rapamycin binds TORC1 to inhibit its function. 
Indeed, TOR was originally identified on the basis of muta-
tions that confer resistance to rapamycin, which is a macro-
cyclic lactone produced by Streptomyces hygroscopicus as 
an antifungal agent. Treatment of yeast cells with rapamycin 
phenocopies nitrogen starvation or inactivation of TOR by 
leading to down-regulation of protein synthesis and upregu-
lation of macroautophagy (delivery of cytoplasmic contents 
to lysosomes and vacuoles). The mechanism by which 
FKBP12-rapamycin inhibits TORC1 is not known but has 
been proposed to include blockage of substrate access or 
dissociation of TOR from associated proteins [22, 23]. Pro-
teins associated with TOR in yeast TORC1 have been identi-
fied as KOG1, TCO89, and LST8, of which only TCO89 has 
no obvious mammalian homolog (Fig. (1)); KOG1 defi-
ciency in yeast resembles the phenotype of rapamycin treat-
ment, suggesting that KOG1 is a positive regulator of TOR, 
an inference also reached with regard to LST8 [10, 24]. 
Knockdown of the mammalian KOG1 homolog (Raptor), 
which interacts with downstream targets of TOR, likewise 
emulates treatment with rapamycin [22, 25, 26]. 
TARGETS OF TORC1 
  Several upstream signaling cues, including growth fac-
tors in mammals, nutrients, and environmental stress such as 
hypoxia and DNA damage regulate TORC1 signaling. Major 
targets of TORC1 include components of the translation ma-
chinery (reviewed in [3]). Such downstream targets include 
the general translation initiation factor 4E-BP which func-
tions to regulate availability of the initiation factor eIF4E, 
essential for cap-dependent initiation of translation [27-29]. 
Another well-established target of the TORC1 complex is 
the S6 protein kinase S6K1, which phosphorylates ribosomal 
protein S6, an event that controls elongation factor 2 kinase, 
but probably not translation of mRNAs with a 5'-oligopy- 
rimidine tract as originally suggested [30-32]. 
TORC1-Mediated Regulation of rDNA Transcription 
  In addition to numerous roles in regulation of translation, 
TORC1 regulates transcription of all genes whose products 
are involved in ribosome biogenesis. Production of rRNA 
accounts for at least 60% of total yeast transcriptional activ-
ity during normal growth, so it is a highly energy- and nutri-
ent-consuming process. To conserve resources, cells must 
therefore limit the production of new ribosomes during nu-
trient starvation. Accordingly, both synthesis and the subse-
quent processing of 35S precursor rRNA is regulated by the 
TOR signaling pathway in both mammalian and yeast cells 
[33, 34].  
  rDNA transcription is confined to the nucleolus, where 
rDNA genes are arranged as hundreds of head-to-tail repeats. 
The primary rRNA transcript is then processed into the ma-
ture rRNAs in the nucleolus, which is also the site of ribo-
some biogenesis. A recent study showed that rapamycin and 
nutrient starvation causes rapid delocalization of RNA Pol I 
from the nucleolus, suggesting a possible mechanism for the 
regulation of rDNA transcription by TOR [35]. These 
authors also found that rDNA chromatin undergoes dramatic 
remodeling and becomes condensed in the presence of ra-
pamycin. Notably, the rapamycin-mediated inhibition of 
rDNA transcription was blocked by a mutation in RPD3, a 
histone deacetylase subunit of the RPD3-SIN3 complex. 
Since RPD3–SIN3 histone deacetylase is important for regu-
lation of chromatin condensation in yeast, and since both 
RPD3 and SIN3 were found to be rapamycin sensitive in a 
genomic rapamycin-sensitivity screen, these findings suggest 
that RPD3-mediated histone H4 deacetylation at rDNA 
chromatin may be a critical step in rDNA transcriptional 
regulation [36, 37]. Further supporting a role for chromatin 
remodeling in TOR-mediated rDNA gene activity is that 
RSC9, a component of the chromatin remodeling complex 
 
 
 
 
 
Fig. (1). Domain organization of TOR kinases. Functional domains depicted include the N-terminal HEAT repeats, the central FAT do-
main, the kinase domain, and the C-terminal FRB domain to which FKBP12-rapamycin associates. Proteins associating with TORC1 include 
TCO89, KOG1, and LST1, of which only TCO89 has no apparent mammalian homolog. 200    Current Genomics, 2009, Vol. 10, No. 3  Xiao and Grove 
RSC (Remodels the Structure of Chromatin), is differentially 
localized to genomic DNA on TOR inactivation [38]. That 
RPD3 was also reported not to be required for rapamycin-
mediated inhibition of Pol I points to mechanisms beyond 
chromatin remodeling [39]. 
  Like Pol II and Pol III, Pol I requires auxiliary factors to 
mediate promoter recognition; for mammalian Pol I, preini-
tiation complex formation requires the upstream binding 
factor UBF and the promoter selectivity factor TIF-IB/SL1 
(TIF-IB in mouse; SL1 in humans) [40-42]. Yeast does not 
encode a UBF homolog, instead the HMGB protein HMO1 
has been reported to be a component of the Pol I machinery 
[43], and yeast Pol I transcription also requires the multi-
functional complex UAF that binds upstream of the core 
promoter [44, 45]. UBF contains several HMG boxes, which 
result in DNA wrapping about the UBF dimer to bring the 
core promoter and upstream control element UCE into prox-
imity, creating an “enhancesome” [46, 47]. It is thought that 
this DNA conformation is required for productive interac-
tions between UBF and TIF-IB/SL1 that manifest in recruit-
ment of Pol I by UBF and stabilization of TIF-IB/SL1 [48]. 
UBF contacts Pol I directly through interaction with PAF53, 
the mammalian homolog of yeast RPA49, and TIF-IB/SL1 
interacts with TIF-IA, the mammalian homolog of yeast 
Rrn3 [49]. TIF-1A/Rrn3 is a regulatory factor that associates 
with initiation-competent subpopulations of Pol I [50, 51].  
  In both yeast and mammals, TOR controls transcription 
by RNA polymerase I via the transcription factor TIF-
IA/Rrn3, as inactivation of TOR impairs formation of the 
transcription initiation complex [34, 51-53]. Using chromatin 
immunoprecipitation assays, it was found that rapamycin 
treatment causes a decrease in the level of Rrn3-Pol I com-
plex at the yeast rDNA promoter and coding region, similar 
to what occurs in stationary phase, suggesting that the de-
crease in transcriptional activity of individual active genes in 
stationary phase is mediated by the TOR signaling system 
through Rrn3-dependent polymerase recruitment [52]. Thus, 
the Pol I-Rrn3 interaction may be a major target of TOR-
dependent regulation of rDNA transcription [51]. 
  Changes in UBF phosphorylation are key to modulating 
rDNA activity during cell cycle progression; for example, 
phosphorylation of the C-terminal activation domain of UBF 
by casein kinase II (CKII) facilitates the interaction between 
UBF and TIF-IB/SL1 [54]. Stimulation of rDNA transcrip-
tion by mTOR requires both activation of S6K1 and phos-
phorylation of the UBF C-terminal domain (but not directly 
by S6K1; [56]). By contrast, rapamycin treatment leads to 
the rapid dephosphorylation of the UBF C-terminal domain, 
which significantly reduces its ability to interact with SL1 
[55].  
  In addition to signaling functions, including the control 
of cellular localization of specific transcription factors as 
discussed below, TOR1 itself is dynamically distributed in 
the cytoplasm and nucleus in yeast. TOR1 nuclear localiza-
tion is nutrient-dependent and rapamycin sensitive, and star-
vation or treatment with rapamycin causes TOR1 to exit 
from the nucleus. TOR1 nuclear localization is critical for 
35S rRNA synthesis, but not for the expression of ribosomal 
protein genes [56]. Thus, effects of TOR signaling on rRNA 
gene activity appear to be exerted at the levels of both chro-
matin remodeling and transcription factor activity, perhaps 
governed by the cellular localization of TOR. 
TORC1-Mediated Regulation of RP Gene Expression 
  Ribosomal protein (RP) genes in eukaryotes are also 
regulated in response to growth stimuli and environmental 
stress. Global transcription profiling revealed that RP gene 
transcription is drastically repressed in response to rapamy-
cin [33, 57]. As for rRNA gene activity, chromatin remodel-
ing has also been implicated in regulation of RP gene ex-
pression in response to TOR signaling. For example, Rohde 
and Cardenas found that expression of RP genes coincides 
with recruitment of the ESA1 histone acetyl transferase to 
RP gene promoters, while inhibition of TOR with rapamycin 
releases ESA1 from RP gene promoters and leads to histone 
H4 deacetylation. Genetic and biochemical evidence demon-
strated that the chromatin deacetylation complex RPD3-
SIN3, also implicated in regulating rDNA gene activity, con-
tributes to the repression of RP gene expression in response 
to TOR inhibition by rapamycin or nutrient limitation [58, 
59]. 
  A number of transcription factors have been implicated 
in regulation of RP gene expression. Genome-wide detection 
of transcription factor binding revealed that the Forkhead-
like transcription factor FHL1, originally isolated as a multi-
copy suppressor of RNA Pol III, is found at yeast RP gene 
promoters [60, 61]. Subsequent studies found that FHL1 may 
function either as a repressor or activator of RP gene tran-
scription, depending on whether it associates with the corep-
ressor CRF1 (Co-repressor with FHL1) or the coactivator 
IFH1 (Interacts with Forkhead). This decision is made based 
on the subcellular localization of CRF1, which is in turn de-
termined by its phosphorylation state. TOR controls the sub-
cellular localization of protein kinase A (PKA) and the PKA-
regulated kinase YAK1 for which CRF1 is a substrate [62-
64]; in actively growing cells, TORC1 negatively regulates 
the activity of YAK1, keeping CRF1 in the cytoplasm, while 
inhibition of TORC1 results in activation of YAK1, which in 
turn phosphorylates CRF1. Phosphorylated CRF1 translo-
cates to the nucleus where it competes with IFH1 for binding 
to FHL1, which is constitutively bound at RP gene promot-
ers [63]. The essential protein IFH1 is recruited to RP gene 
promoters through the forkhead-associated domain of FHL1 
[62, 64, 65]; FHL1 and IFH1 were shown to associate almost 
exclusively with RP promoters, and the level of IFH1 associ-
ated with RP promoters suggested to determine the level of 
transcription [64]. Accordingly, IFH1 is thought to be an 
essential regulator of RP gene transcription (Fig. (2)). That 
additional factors must contribute to TOR-mediated regula-
tion of RP gene activity was indicated by the observation 
that CRF1 may not be essential for rapamycin-dependent 
down-regulation of RP gene activity, depending on strain 
background, and that simply tethering of FHL1 to RP gene 
promoters is insufficient to cause transcriptional activation, 
in spite of the fact that such tethered FHL1 does recruit IFH1 
[66]. 
  Although yeast FHL1 has a domain that is related to the 
DNA binding domain of the Drosophila Forkhead protein, 
FHL1 was reported not to bind DNA in vitro [67]. Thus, the 
binding of FHL1 to an RP promoter is likely to be either Coordination of Ribosomal Protein  Current Genomics, 2009, Vol. 10, No. 3    201 
indirect or facilitated by other proteins. One such candidate 
for FHL1 recruitment is the repressor-activator protein 1 
(Rap1), long known to be involved in the transcription of RP 
genes; most RP genes contain Rap1 binding sites at their 
promoters [68, 69]. However, Rap1 binds to many sites in 
the yeast genome and acts as an activator at some and as a 
repressor at others, as its name implies. Further, not all RP 
gene promoters contain Rap1 binding sites [70], suggesting 
that additional protein(s) contribute to FHL1 recruitment.  
  The complexity of the TOR pathway is further under-
scored by the reported involvement of yet another transcrip-
tion factor, Sfp1, a key cell size regulator, in regulating RP 
gene expression in response to nutrients and stress [71]. Un-
der optimal growth conditions, Sfp1 is localized to the nu-
cleus, bound to the promoters of RP genes where it activates 
RP gene expression. In response to inhibition of TOR signal-
ing, Sfp1 is released from RP gene promoters, and down-
regulation of RP gene transcription occurs concomitant with 
Sfp1 leaving the nucleus. That Sfp1 remains localized to the 
nucleus in a strain constitutively expressing high PKA activ-
ity in spite of rapamycin treatment suggests that Sfp1 may be 
regulated by the branch of the TOR pathway that depends on 
PKA, similar to the regulation of CRF1 localization [63, 71]. 
Analysis of genetic interactions further suggested that Sfp1 
influences RP gene transcription via FHL1 and IFH1, and 
that the association of IFH1 and FHL1 with RP gene pro-
moters was reduced by approximately four-fold and two-
fold, respectively, in sfp1 cells [72]. As for the role of 
CRF1 in communicating downstream signals of the TOR 
pathway, the role of Sfp1 may be strain-dependent, as a sub-
sequent genome-wide ChIP analyses suggested only limited 
association of Sfp1 with RP genes [73]. Thus, while different 
transcription factors have been variously implicated in medi-
ating responses to TOR signaling, suggesting the existence 
of more than one mechanism by which such signals are con-
verted to changes in gene activity, signaling through FHL1 
appears to be the primary pathway. 
Coordination of rRNA and RP Gene Expression in Re-
sponse to TOR Signaling  
  As summarized above, an effect of TOR inactivation on 
rRNA and RP gene expression has been well established, 
although the molecular basis for the response remains to be 
fully elucidated. Notably, recent evidence has finally fur-
nished a link that may provide a clue to the mechanism by 
which transcriptional activity of the different RNA polym-
erase machineries may be coordinated in response to TOR 
signaling. This link comes in the form of the yeast HMGB 
homolog HMO1. HMGB proteins are conserved architec-
tural proteins that bind DNA without sequence specificity, 
but with preference for DNA with structural distortions. As 
for mammalian HMGB homologs, HMO1 is composed of 
two HMG boxes, box A and box B. Box A has low affinity 
for DNA but is required for DNA structural specificity and 
for DNA bending, whereas box B is required for high affin-
ity DNA binding [74, 75]. Genetic analysis showed that 
HMO1 is important for maximal transcription of rDNA [43]. 
While the molecular basis for the involvement of HMO1 in 
Pol I transcription is unknown, it is noteworthy that HMO1 
overexpression suppresses an rpa49 mutation, as RPA49 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). HMO1 associates with both rRNA and RP gene promoters to coordinate gene expression in response to TORC1 activity. On 
rDNA, HMO1 associates with both promoter and coding regions of transcriptionally active rDNA. Proposed functions include a role akin to 
that reported for mammalian UBP in transcriptional initiation and a role in coordinating transcriptional elongation with pre-rRNA process-
ing, to which Utp22 and Rrp7 contribute. On most RP gene promoters, Rap1 sites are further upstream than on other Rap1-dependent genes, 
and association of Rap1 appears to be required for the subsequent cooperative binding of HMO1 and FHL1 at IFHL sites. When TORC1 is 
active, the coactivator IFH1 binds FHL1 to activate RP gene transcription. When TORC1 is inactive, phosphorylated CRF1 translocates to 
the nucleus to compete with IFH1 for binding to FHL1 and repress transcription. IFH1 is found in the “CURI” complex also containing 
Utp22, Rrp7, and CKII, with which FHL1 also associates. HMO1 dissociates from both classes of genes on inactivation of TORC1. 202    Current Genomics, 2009, Vol. 10, No. 3  Xiao and Grove 
corresponds to the mammalian PAF53 which interacts di-
rectly with the HMG-box-containing transcription factor 
UBF; as noted above, yeast does not encode a UBF homolog 
[43, 48, 49]. It is therefore tempting to speculate that HMO1 
may serve to configure the yeast Pol I promoter for optimal 
transcriptional activity, akin to the enhancesome structure 
proposed for UBF [46, 47].  
  A seminal study by Hall and coworkers demonstrated 
that HMO1 associates throughout the rDNA locus [76]. 
Their study also confirmed that HMO1 is required for 
maximal transcription of rRNA genes and demonstrated a 
role for HMO1 in rRNA maturation. Considering the local-
ization of HMO1 throughout the rDNA locus, its reported 
role in rRNA processing, and recent evidence linking RNA 
Pol I transcriptional elongation with rRNA maturation, it is 
conceivable that HMO1 participates in coordinating these 
activities [77]. Importantly, HMO1 was also found to associ-
ate with most RP gene promoters and to do so in a Rap1-
dependent fashion [76]. While Rap1 appears to be required 
for association of HMO1 with RP gene promoters, it is not 
sufficient, as evidenced by its localization to other genomic 
loci to which HMO1 does not associate. Notably, HMO1 
association is reduced in an fhl1 strain, while inactivation 
of  HMO1 completely eliminates association of FHL1 and 
IFH1 with RP genes [76]. These data indicate that HMO1 
and FHL1 bind cooperatively to RP gene promoters, and that 
Rap1 may promote this association.  
  Using a global genetic approach, Berger et al. subse-
quently reported that HMO1 specifically interacts with the 
Pol I-transcribed region of the rDNA locus, pointing to a role 
in elongation, and confirmed its association with a subset of 
RP gene promoters [78]. This is consistent with an inde-
pendent report indicating that HMO1 associates with the 35S 
rRNA gene in an RNA Pol I-dependent manner [73]. Nota-
bly, HMO1 was seen to dissociate from both rDNA and 
some RP gene promoters upon rapamycin treatment, and 
HMO1 deletion was shown to reduce the TORC1-dependent 
repression of RP gene expression [78]. These results clearly 
link HMO1 to the rapamycin-dependent TOR pathway and 
suggest that HMO1 is involved in coordinating rDNA tran-
scription by Pol I and RP gene expression by Pol II in re-
sponse to TOR signaling. 
CONCLUSION 
  The molecular mechanisms underlying the role of HMO1 
in coordinating rRNA and RP gene transcription in response 
to TOR-mediated signals remain to be determined. In the 
case of rDNA, HMO1 has been proposed to serve roles akin 
to those fulfilled by UBF in mammalian transcriptional ini-
tiation as well as in linking transcriptional elongation with 
pre-rRNA processing. Regardless of its specific function(s), 
it is clear that HMO1 abandons the rDNA locus when 
TORC1 is inhibited [78]. For UBF, dephosphorylation in 
response to rapamycin treatment is accompanied by reduced 
recruitment of Pol I [55]. Whether HMO1 is likewise subject 
to covalent modification in a rapamycin-dependent fashion 
remains to be determined.  
  At RP gene promoters, several transcription factors have 
been implicated in mediating downstream effects of TOR 
signaling. While the role of Sfp1 appears particularly uncer-
tain, a consensus is emerging based on consistent reports 
from several groups (Fig. (2)). At most RP gene promoters, 
HMO1 appears to associate in a Rap1-dependent fashion, 
followed or accompanied by FHL1; however, at the promot-
ers to which HMO1 only associates modestly, FHL1 binding 
appears independent of HMO1 [73]. The transcription factor 
IFH1 is essential, consistent with its reported role as a co-
activator of RP gene transcription; if IFH1 is absent, the co-
repressor CRF1 would also encounter no competition for 
binding to FHL1, thus potentially abolishing even basal lev-
els of RP transcription. Depending on genetic background, a 
rapamycin-mediated down-regulation of RP gene activity 
may still be seen when CRF1 is inactivated; however, the 
basis for this observation remains unknown and has been 
suggested to involve more than one gene product [66]. One 
possible clue derives from the observation that IFH1 is found 
to a significant extent in a complex named CURI, composed 
of casein kinase II (CKII), Utp22, Rrp7 and IFH1), a com-
plex with which FHL1 also loosely associates [79]. Notably, 
both Utp22 and Rrp7 have been implicated in pre-rRNA 
processing, a process in which HMO1 is also involved. It is 
possible that TOR-dependent sequestration of IFH1 in the 
CURI complex limits its availability as an RP gene activator, 
causing down-regulation of RP gene expression on inhibition 
of the TOR pathway. Activation of rDNA transcription may 
lead to disruption of CURI as Utp22 and Rrp7 engage in pre-
rRNA processing, thus releasing IFH1 to activate RP gene 
expression [79]. Whether HMO1 participates in this pro-
posed scenario has not been addressed; however, HMO1 has 
been reported to interact directly with Utp22 [80], consistent 
with both proteins participating in pre-rRNA processing, 
suggesting the possibility that CURI may be recruited to 
both rRNA and RP genes by interaction with HMO1. 
  As HMO1 is non-sequence-specific in its DNA binding 
[74, 75], it is likely recruited to RP gene promoters by asso-
ciation with sequence-specific factors; that FHL1 fails to 
bind DNA in vitro, even in the presence of Rap1 [67], com-
bined with the co-dependence of HMO1 and FHL1 for bind-
ing to RP genes [76], suggests that HMO1 (or another factor, 
perhaps Sfp1) may be required to stabilize it on the DNA. 
HMO1 was reported either to have no effect or to cause a 
mild activation of RP gene transcription [76, 78]; such ef-
fects may be due to its interaction with TFIID, which has 
been reported to affect occupancy of TFIID at certain RP 
gene promoters as well as to participate in start site selection 
of a subset of Pol II genes [81]. As for rDNA, the mecha-
nism by which HMO1 leaves the RP gene promoters follow-
ing inhibition of the TOR pathway is not known.  
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TOR =  Target  of  Rapamycin 
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